Explore the vast range of titles available.

The National Collegiate Athletic Association (NCAA) is a private, nonprofit organization whose mission is undeniably inseparable from higher education. While the courts historically served as the sole reviewer of many of the NCAA's actions and policies, interest in name, image, and likeness (NIL) laws has sparked a legislative movement. But recent legislative proposals to implement NIL fall short of legitimately holding the NCAA accountable. The Department of Education, tasked in part with overseeing postsecondary education across the nation, is well-equipped to regulate the NCAA's lapses in its governance of college athletics pertaining to gender inequality, sexual misconduct, discrimination, and education. The NCAA's impact on higher education warrants regulation, and the Department of Education is the agency best suited for the job. Congress should extend the oversight authority of the Assistant Secretary for Postsecondary Education to oversee and work with the NCAA to promote a more equitable college athletic environment and to implement NIL opportunities in an equitable manner.

While some states, such as New Jersey, provide an exemption so that issuers do not have to register their securities in the state when offering them through an ESPP, others may require that issuers take certain steps before taking advantage of an exemption. Because employers must extend the option to participate in an ESPP to all of their employees, this can pose a challenge for employers with out-of-state employees. New York General Business Law Section 359-F(2)(e) exempts securities offered in connection with an \"employees' stock purchase, savings, pension, profit-sharing or similar benefit plan\" from registration in New York state, provided that the issuer files an application with the attorney general and that the attorney general grants an exemption. Katrina L. Berishaj, managing counsel in the Washington, D.C., office of Stradley Ronon Stevens & Young, LLP, and co-chair of the firm's fiduciary governance practice, advises financial services clients, including banks, trust companies, broker-dealers, investment advisers, insurance companies and institutional investors, on issues arising under the fiduciary and prohibited transaction rules of the Employee Retirement Income Security Act and the Internal Revenue Code.

Rip currents (“rips”) are the leading cause of drowning on surf beaches worldwide. A major contributing factor is that many beachgoers are unable to identify rip currents. Previous research has attempted to quantify beachgoers' rip identification ability using photographs of rip currents without identifying whether this usefully translates into an ability to identify a rip current in situ at the beach. This study is the first to compare beachgoers ability to identify rip currents in photographs and in situ at a beach in New Zealand (Muriwai Beach) where a channel rip current was present. Only 22 % of respondents were able to identify the in situ rip current. The highest rates of success were for males (33 %), New Zealand residents (25 %), and local beach users (29 %). Of all respondents who were successful at identifying the rip current in situ, 62 % were active surfers/bodyboarders, and 28 % were active beach swimmers. Of the respondents who were able to identify a rip current in two photographs, only 34 % were able to translate this into a successful in situ rip identification, which suggests that the ability to identify rip currents by beachgoers is worse than reported by previous studies involving photographs. This study highlights the difficulty of successfully identifying a rip current in reality and that photographs are not necessarily a useful means of teaching individuals to identify rip currents. It advocates for the use of more immersive and realistic education strategies, such as the use of virtual reality headsets showing moving imagery (videos) of rip currents in order to improve rip identification ability.

Ocular redness (OR) is a common clinical presentation that can significantly impact patients' health-related quality of life (HRQoL), yet treatment options have historically been limited by side effects and efficacy concerns. Brimonidine tartrate 0.025% represents a newer therapeutic option, but real-world perspectives from healthcare professionals (HCPs) on its clinical utility remain understudied. A cross-sectional exploratory qualitative interview study was conducted with 18 ophthalmologists purposively recruited from a sponsor-acquired list. Participants had experience prescribing or recommending brimonidine tartrate 0.025% and were interviewed across Spain, Portugal, Poland, the United States, and Greece. Semi-structured interviews explored current treatment landscapes, unmet needs, and experiences with brimonidine tartrate 0.025%. Transcripts were analysed using qualitative content analysis. Participants reported OR as highly prevalent in their practice, with dry eye disease being the most commonly cited underlying cause. HCPs described significant HRQoL impact on patients, including social embarrassment, workplace concerns, and emotional distress. Prior to brimonidine tartrate 0.025%, treatment options were limited, with traditional vasoconstrictors avoided due to rebound redness and tachyphylaxis. All participants reported brimonidine tartrate 0.025% as effective, with rapid onset and good tolerability. Key advantages included lack of rebound redness and suitability for various patient types. This study with brimonidine tartrate 0.025% prescribers found it addresses a significant unmet need in OR management, providing effective relief with improved safety profile compared to traditional options. However, emphasis on proper diagnosis and use remains crucial.

Background Eating disorders (EDs) are serious, often chronic, conditions associated with pronounced morbidity, mortality, and dysfunction increasingly affecting young people worldwide. Illness progression, stages and recovery trajectories of EDs are still poorly characterised. The STORY study dynamically and longitudinally assesses young people with different EDs (restricting; bingeing/bulimic presentations) and illness durations (earlier; later stages) compared to healthy controls. Remote measurement technology (RMT) with active and passive sensing is used to advance understanding of the heterogeneity of earlier and more progressed clinical presentations and predictors of recovery or relapse. Methods STORY follows 720 young people aged 16–25 with EDs and 120 healthy controls for 12 months. Online self-report questionnaires regularly assess ED symptoms, psychiatric comorbidities, quality of life, and socioeconomic environment. Additional ongoing monitoring using multi-parametric RMT via smartphones and wearable smart rings (‘Ōura ring’) unobtrusively measures individuals’ daily behaviour and physiology (e.g., Bluetooth connections, sleep, autonomic arousal). A subgroup of participants completes additional in-person cognitive and neuroimaging assessments at study-baseline and after 12 months. Discussion By leveraging these large-scale longitudinal data from participants across ED diagnoses and illness durations, the STORY study seeks to elucidate potential biopsychosocial predictors of outcome, their interplay with developmental and socioemotional changes, and barriers and facilitators of recovery. STORY holds the promise of providing actionable findings that can be translated into clinical practice by informing the development of both early intervention and personalised treatment that is tailored to illness stage and individual circumstances, ultimately disrupting the long-term burden of EDs on individuals and their families.